Holger Eidtmann

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer et al. · Journal of Clinical Oncology · 2012 · 2.7K citations

Medicine, Oncology, Breast Oncology +15

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +14

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Breast Oncology +12

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Michael Gnant, Brigitte Mlineritsch, Walter Schippinger et al. · New England Journal of Medicine · 2009 · 1K citations · Full text

Medicine, Oncology, Pharmacology +13

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

Roberto Salgado, Carsten Denkert, Christine Campbell et al. · JAMA Oncology · 2015 · 606 citations · Full text

Medicine, Immunology, Oncology +17